logo
logo

Synerkine Pharma Raises Eur 3.5 Million In An Extended Series A Financing

Dec 16, 2021•almost 4 years ago

Amount Raised

€3.5 Million

Round Type

series a

Naarden

Description

Synerkine Pharma B.V. announced today that it has added EUR 3.5 million to its Series A funding. The extension was led by Flerie Invest, with support from existing investors Thuja Capital and Utrecht Holdings.

Company Information

Company

Synerkine Pharma

Location

Naarden, Noord-Holland, NLD

About

Synerkine Pharma B.V. focuses on development of novel fusion proteins that combine the immunoregulatory activity of different cytokines. These fusion proteins have unique benefits over the individual cytokines and modulate a broad number of targets including key elements in the pain pathway. This provides treatment options for chronic pain conditions that clearly differentiate from the mechanism of action of current analgesic drugs holds tremendous therapeutic and commercial potential. Synerkine Pharma B.V. was founded in 2018 and is a spin-off of the University Medical Center Utrecht (UMCU), the Netherlands.